The Next-Generation Biotherapeutic Solutions for Tissue Repair and Regeneration
The company’s unique platform is a concentrate of proteins enriched in bromelain, which is extracted from the pineapple stem, purified and enriched utilizing our proprietary enzymes enrichment technology.
Our strategy leverages our breakthrough enzymatic technology platform into diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. Our current portfolio is focused on next-generation bio active therapies for burn and wound care and biological medicinal products for tissue repair.
MediWound’s enzyme enrichment technology (EET) harnesses nature’s wisdom while maximizing its biotherapeutic properties for medical therapies.
Enzymes enrichment technology is characterized by the ability to enrich the natural substance with its most active components while maintaining their highest activity during all process stages, from plant harvesting through pharmaceutical product on the shelf.
From Plant to Drug
Our pharmaceutical product ingredient (API) is complex mixture of proteins, enriched in bromelain, extracted from the stem of the pineapple. The API possess various pharmacological properties, including:
NexoBrid, our commercial biological orphan product for debridement of severe thermal burns. NexoBrid is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. Nexobrid is currently marketed in the European Union and other International markets and at a registration-stage in the U.S. NexoBrid is supported by U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx, our next-generation bioactive topical therapeutic for debridement of chronic and hard to heal wounds, is a product candidate in advanced stages of development. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MW005, our third biological drug for the treatment of non-melanoma skin cancer. MW005 is a clinical-staged product candidate under development.